Arsenic: A potentially useful poison for Hedgehog-driven cancers

Journal of Clinical Investigation

Volumn 121, Issue 1, 2011, Pages 14-16

  Raju, G Praveen ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 CHLORO N [4 CHLORO 3 (2 PYRIDINYL)PHENYL] 4 METHANESULFONYLBENZAMIDE; ARSENIC TRIOXIDE; SMOOTHENED PROTEIN; SONIC HEDGEHOG PROTEIN;

ANTINEOPLASTIC ACTIVITY; CANCER GROWTH; CANCER INHIBITION; CANCER RESISTANCE; DISEASE COURSE; DNA BINDING; DRUG BINDING; DRUG TARGETING; EWING SARCOMA; HUMAN; MEDULLOBLASTOMA; MOLECULARLY TARGETED THERAPY; NONHUMAN; NOTE; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; SIGNAL TRANSDUCTION; TREATMENT RESPONSE;

ANIMALS; ANTINEOPLASTIC AGENTS; ARSENICALS; CELL LINE, TUMOR; HEDGEHOG PROTEINS; HUMANS; MEDULLOBLASTOMA; MICE; MODELS, BIOLOGICAL; NEOPLASMS; OXIDES; RECEPTORS, G-PROTEIN-COUPLED; SARCOMA, EWING'S; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS;

EID: 78650933529     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI45692     Document Type: Note

References (21)

1. Emadi A, Gore SD. Arsenic trioxide - An old drug rediscovered. Blood Reviews. 2010;24(4-5):191-199.
2. Sun HD, Ma L, Hu XC, Zhang TD. Ai-Lin I treated 32 cases of acute promyelocytic leukemia. Chin J Integrated Tradit West Med. 1992;12:170-172.
3. Soignet SL, et al. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol. 2001;19(18):3852-3860.
4. Chen GQ, et al. In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia. Blood. 1996;88(3):1052-1061.
5. Porter AC, Fanger GR, Vaillancourt RR. Signal transduction pathways regulated by arsenate and arsenite. Oncogene. 1999;18(54):7794-7802. (Pubitemid 30052764)
6. Kapahi P, et al. Inhibition of NF-kappa B activation by arsenite through reaction with a critical cysteine in the activation loop of Ikappa B kinase. J Biol Chem. 2000;275(46):36062-36066.
7. Jiang J, Hui CC. Hedgehog signaling in development and cancer. Dev Cell. 2008;15(6):801-812.
8. Teglund S, Toftgard R. Hedgehog beyond medulloblastoma and basal cell carcinoma. Biochim Biophys Acta. 2010;1805(2):181-208.
9. Tremblay MR, McGovern K, Read MA, Castro AC. New developments in the discovery of small molecule Hedgehog antagonists. Curr Opin Chem Biol. 2010;14(3):428-435.
10. Taylor MD, et al. Mutations in SUFU predispose to medulloblastoma. Nat Genet. 2002;31(3):306-310.
11. Zwerner JP, et al. The EWS/FLI1 oncogenic transcription factor deregulates Gli1. Oncogene. 2008;27(23):3282-3291.
12. Rudin CM, et al. Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449. N Engl J Med. 2009;361(12):1173-1178.
13. Beauchamp EM, et al. Arsenic trioxide inhibits human cancer cell growth and tumor development in mice by blocking Hedgehog/GLI pathway. J Clin Invest. 2011;121(1):148-160.
14. Beauchamp E, et al. GLI1 is a direct transcriptional target of EWS-FLI1 oncoprotein. J Biol Chem. 2009;284(1):9074.
15. Gore SD, et al. Single cycle of arsenic trioxide-based consolidation chemotherapy spares anthracycline exposure in the primary management of acute promyelocytic leukemia. J Clin Oncol. 2010;28(6):1047-1053.
16. Au WY, Tam S, Fong BM, Kwong YL. Determinants of cerebrospinal fluid arsenic concentration in patients with acute promyelocytic leukemia on oral arsenic trioxide therapy. Blood. 2008;112(9):3587-3590.
17. Knipp S, Gattermann N, Schapira M, Kaferstein H, Germing U. Arsenic in the cerebrospinal fluid of a patient receiving arsenic trioxide for relapsed acute promyelocytic leukemia with CNS involvement. Leuk Res. 2007;31(11):1585-1587.
18. Kim J, Lee JJ, Kim J, Gardner D, Beachy PA. Arsenic antagonizes the Hedgehog pathway by preventing ciliary accumulation and reducing stability of the Gli2 transcriptional effector. Proc Natl Acad Sci U S A. 2010;107(30):13432-13437.
19. Bai LY, et al. Differential expression of Sonic hedgehog and Gli1 in hematological malignancies. Leukemia. 2008;22(1):226-228.
20. Lauth M, Bergstrom A, Shimokawa T, Toftgard R. Inhibition of GLI-mediated transcription and tumor cell growth by small molecule antagonists. Proc Natl Acad Sci U S A. 2007;104(20):8455-8460.
21. Kimura H, Ng JM, Curran T. Transient inhibition of the hedgehog pathway in young mice causes permanent defects in bone structure. Cancer Cell. 2008;13(3):249-260.